These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35334612)

  • 1. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
    Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
    Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.
    Basoulis D; Mastrogianni E; Eliadi I; Papadopoulou M; Psichogiou M
    HIV Med; 2024 Oct; 25(10):1135-1144. PubMed ID: 39031579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
    Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
    Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
    J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
    Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
    Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
    Iversen J; Wand H; McManus H; Dore GJ; Maher L
    Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus.
    Bar N; Bensoussan N; Rabinowich L; Levi S; Houri I; Ben-Ami Shor D; Shibolet O; Mor O; Weitzman E; Turner D; Katchman H
    Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
    PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiviral treatment for hepatitis C among injecting drug users in the era of direct-acting antiviral agents].
    Pan L; Pang L
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):893-896. PubMed ID: 33105938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
    Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.